CHGA on Nasdaq
Change Agents Corporation.
American computer programming services company based in Freehold. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with KHEOBA Ltd, Perpetuals.com Ltd or Alpha Technology Group Ltd, or pick any stock.
- TickerCHGA on Nasdaq1
- IndustryServices-Computer Programming Services1
- HeadquartersFreehold, New Jersey1
- Incorporated inDE2
- Business address4400 Route 9, Suite 3100, Freehold, Nj 077282
- Filer categoryNon-accelerated filer, Smaller reporting company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Avalon Quantum AI, LLC, our wholly owned subsidiary formed in connection with our acquisition of RPM Interactive, Inc. in December 2025.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| INCOME (LOSS) FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO | $392.7K | -$846.6K |
| Advertising and marketing expenses | $843.5K | $237.7K |
| Professional fees | $5.3M | $1.6M |
| Compensation and related benefits | $1.1M | $1.3M |
| Other general and administrative expenses | $784.8K | $857.9K |
| Total Other Operating Expenses | $8.0M | $4.0M |
| LOSS FROM OPERATIONS | -$7.6M | -$4.8M |
| Interest expense - amortization of debt discount and debt issuance costs | -$1.1M | -$1.3M |
| Interest expense - other | -$320.3K | -$325.5K |
| Interest expense - related party | -$42.4K | |
| Debt modification charge | -$838.8K | |
| Change in fair value of derivative liability | $538.2K | $374.4K |
| Loss on extinguishment of debt | -$9.1M | |
| Other income (expense) | $67.6K | -$74.2K |
| Total Other Expense, net | -$9.9M | -$2.2M |
| LOSS BEFORE INCOME TAXES | -$17.5M | -$7.0M |
| NET LOSS FROM CONTINUING OPERATIONS | -$17.5M | -$7.0M |
| NET LOSS FROM DISCONTINUED OPERATIONS | -$742.1K | -$863.8K |
| NET LOSS | -$18.3M | -$7.9M |
| NET LOSS AFTER NONCONTROLLING INTEREST | -$18.3M | -$7.9M |
| DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS | $162.5K | |
| NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | -$18.1M | -$7.9M |
| Basic, continuing operations (in Dollars per share) | -$5 | -$8 |
| Diluted, continuing operations (in Dollars per share) | -$5 | -$8 |
| Basic, discontinued operations (in Dollars per share) | -$0 | -$1 |
| Diluted, discontinued operations (in Dollars per share) | -$0 | -$1 |
| Net Loss Per Common Share Attributable Common Shareholders basic (in Dollars per share) | -$5.64 | -$8.44 |
| Net Loss Per Common Share Attributable Common Shareholders diluted (in Dollars per share) | -$5.64 | -$8.44 |
| Weighted Average Common Shares Outstanding Basic (in Shares) | 3.2M shares | 936.6K shares |
| Weighted Average Common Shares Outstanding diluted (in Shares) | 3.2M shares | 936.6K shares |
| Unrealized foreign currency translation loss | -$9.4K | -$273 |
| COMPREHENSIVE LOSS | -$18.3M | -$7.9M |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | -$18.3M | -$7.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $109.1K | $2.7M | |
| Receivable from sale of equity method investment | $748.0K | ||
| Prepaid expense and other current assets | $282.2K | $255.1K | |
| Current assets of discontinued operations | $356.6K | $323.2K | |
| Total Current Assets | $1.5M | $3.2M | |
| Operating lease right-of-use assets, net | $4.7K | ||
| Property and equipment, net | $727 | $1.3K | |
| Intangible assets, net | $2.2M | ||
| Goodwill | $12.8M | ||
| Equity method investments, net | $10.6M | ||
| Non-current assets of discontinued operations | $6.9M | $7.1M | |
| Total Non-current Assets | $21.9M | $17.7M | |
| Total Assets | $23.4M | $21.0M | |
| Accrued professional fees | $1.8M | $611.5K | |
| Accrued research and development fees | $153.8K | $153.8K | |
| Accrued payroll liability and compensation | $1.1M | $501.3K | |
| Accrued litigation settlement | $363.4K | $373.4K | |
| Accrued liabilities and other payables | $281.1K | $228.8K | |
| Operating lease obligation | $6.0K | $10.7K | |
| Derivative liability | $34.2K | $127.5K | |
| Stock subscription liability | $150.0K | ||
| Bridge loan payable, net | $197.3K | ||
| Convertible note payable, net | $737.0K | $2.1M | |
| Current liabilities of discontinued operations | $6.1M | $5.9M | |
| Total Current Liabilities | $14.1M | $13.9M | |
| Non-current liabilities of discontinued operations | $23.5K | ||
| Total Non-current Liabilities | $23.5K | ||
| Total Liabilities | $14.2M | $13.9M | |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,857,476 shares issued and 4,854,009 shares outstanding at December 31, 2025; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024 | $486 | $145 | |
| Additional paid-in capital | $88.4M | $72.0M | |
| Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2025 and 2024 | -$522.5K | -$522.5K | |
| Accumulated deficit | -$105.9M | -$87.7M | |
| Statutory reserve | $6.6K | $6.6K | |
| Accumulated other comprehensive loss | -$241.4K | -$232.0K | |
| Total Avalon GloboCare Corp. stockholders' equity | $9.2M | $7.1M | |
| Total Equity | $9.2M | $7.1M | $7.4M |
| Total Liabilities and Equity | $23.4M | $21.0M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 4.9M shares | 4.9M shares | |
| Common stock, shares outstanding (in Shares) | 1.4M shares | 1.4M shares | |
| Treasury stock (in Shares) | 3.5K shares | 3.5K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $109.1K | $2.7M | |
| Receivable from sale of equity method investment | $748.0K | ||
| Prepaid expense and other current assets | $282.2K | $255.1K | |
| Current assets of discontinued operations | $356.6K | $323.2K | |
| Total Current Assets | $1.5M | $3.2M | |
| Operating lease right-of-use assets, net | $4.7K | ||
| Property and equipment, net | $727 | $1.3K | |
| Intangible assets, net | $2.2M | ||
| Goodwill | $12.8M | ||
| Equity method investments, net | $10.6M | ||
| Non-current assets of discontinued operations | $6.9M | $7.1M | |
| Total Non-current Assets | $21.9M | $17.7M | |
| Total Assets | $23.4M | $21.0M | |
| Accrued professional fees | $1.8M | $611.5K | |
| Accrued research and development fees | $153.8K | $153.8K | |
| Accrued payroll liability and compensation | $1.1M | $501.3K | |
| Accrued litigation settlement | $363.4K | $373.4K | |
| Accrued liabilities and other payables | $281.1K | $228.8K | |
| Operating lease obligation | $6.0K | $10.7K | |
| Derivative liability | $34.2K | $127.5K | |
| Stock subscription liability | $150.0K | ||
| Bridge loan payable, net | $197.3K | ||
| Convertible note payable, net | $737.0K | $2.1M | |
| Current liabilities of discontinued operations | $6.1M | $5.9M | |
| Total Current Liabilities | $14.1M | $13.9M | |
| Non-current liabilities of discontinued operations | $23.5K | ||
| Total Non-current Liabilities | $23.5K | ||
| Total Liabilities | $14.2M | $13.9M | |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,857,476 shares issued and 4,854,009 shares outstanding at December 31, 2025; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024 | $486 | $145 | |
| Additional paid-in capital | $88.4M | $72.0M | |
| Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2025 and 2024 | -$522.5K | -$522.5K | |
| Accumulated deficit | -$105.9M | -$87.7M | |
| Statutory reserve | $6.6K | $6.6K | |
| Accumulated other comprehensive loss | -$241.4K | -$232.0K | |
| Total Avalon GloboCare Corp. stockholders' equity | $9.2M | $7.1M | |
| Total Equity | $9.2M | $7.1M | $7.4M |
| Total Liabilities and Equity | $23.4M | $21.0M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 4.9M shares | 4.9M shares | |
| Common stock, shares outstanding (in Shares) | 1.4M shares | 1.4M shares | |
| Treasury stock (in Shares) | 3.5K shares | 3.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss from continuing operations | -$17.5M | -$7.0M |
| Depreciation and amortization of intangible assets | $94.4K | $611 |
| Amortization of operating lease right-of-use asset | $64.4K | $122.6K |
| Stock-based compensation and service expense | $1.8M | $521.5K |
| (Income) loss from equity method investment | -$392.7K | $846.6K |
| Distribution of earnings from equity method investment | $611.9K | |
| Amortization of debt issuance costs and debt discount | $1.1M | $1.3M |
| Change in fair market value of derivative liability | -$538.2K | -$374.4K |
| Impairment of laboratory equipment | $111.0K | |
| Debt modification charge | $688.8K | |
| Loss on extinguishment of debt | $9.1M | |
| Security deposit | $17.5K | |
| Prepaid expense and other assets | -$22.3K | -$107.0K |
| Accrued liabilities and other payables | $1.8M | -$1.2M |
| Accrued liabilities and other payables - related parties | -$14.1K | |
| Operating lease obligation | -$64.4K | -$122.6K |
| NET CASH USED IN OPERATING ACTIVITIES FROM CONTINUING OPERATIONS | -$4.6M | -$4.7M |
| Payment for equity interest purchase | -$100.0K | |
| Cash acquired on acquisition | $14.0K | |
| Proceeds from sale of equity method investment | $1.1M | |
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES FROM CONTINUING OPERATIONS | $1.1M | -$100.0K |
| Proceeds from issuance of convertible debt and warrants | $3.4M | |
| Proceeds from issuance of convertible debt | $200.0K | |
| Payments of convertible debt issuance costs | -$282.7K | |
| Repayments of convertible debt | -$3.4M | |
| Repayments of loan payable - related party | -$400.0K | |
| Proceeds from stock subscription liability | $150.0K | |
| Advance from pending sale of noncontrolling interest in subsidiary | $50.0K | $2.1M |
| Proceeds from issuance of convertible preferred stock | $300.0K | $3.5M |
| Payments of convertible preferred stock issuance costs | -$10.0K | |
| Proceeds from issuance of bridge loan | $300.0K | |
| Proceeds from issuance of common stock and warrants | $475.5K | |
| Payments of offering costs | -$64.7K | |
| Proceeds from equity offering | $2.9M | |
| Disbursements for equity offering costs | -$138.4K | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS | $1.4M | $7.6M |
| Net cash used in operating activities from discontinued operations | -$407.4K | -$290.0K |
| Net cash used in investing activities from discontinued operations | -$35.9K | |
| NET CASH FLOWS USED IN DISCONTINUED OPERATIONS | -$443.3K | -$290.0K |
| EFFECT OF EXCHANGE RATE ON CASH - CONTINUING OPERATIONS | -$9.0K | $1.4K |
| NET (DECREASE) INCREASE IN CASH | -$2.5M | $2.6M |
| Interest | $916.6K | $1.1M |
| Common stock issued for future services | $8.5K | |
| Common stock issued for accrued liabilities | $42.4K | $60.0K |
| Receivable related to sale of equity method investment | $1.7M | |
| Related party payable extinguished upon sale of equity method investment | $632.9K | |
| Series B Convertible Preferred Stock extinguished related to sale of equity method investment | $11.0M | |
| Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock | $9.0M | |
| Warrants issued as convertible note payable finder's fee | $40.9K | |
| Warrants issued with convertible note payable recorded as debt discount | $438.6K | |
| Common stock issued as convertible note payable commitment fee | $26.8K | $320.5K |
| Equity method investment payable paid by a related party | $566.7K | |
| Reclassification of deferred offering costs | $175.1K | |
| Settlement of derivative liability | $176.5K | $2.4K |
| Issuance of common stock upon cashless exercise of stock warrants | $43 | $4 |
| Initial ROU asset and lease liability | $127.5K | |
| Conversion of convertible note payable and accrued interest into common stock | $2.2M | |
| Deferred financing costs in accrued liabilities | $45.0K | |
| Legal fees recorded to receivable from sale of equity method investment | $50.0K | |
| Reclassification of related party loan payable and accrued expenses to advance from related party | $500.0K | |
| Shares issued for adjustments for 1:15 reverse split | $21 | |
| Bridge loan issuance costs in accrued liabilities | $18.8K | |
| Common stock issued as convertible note payable commitment fee included in accrued liabilities | $138.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Change Agents Corporation., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
20202025
- Chief executive officerMeng Li Jul 13, 2026 to now12
- Chief executive officerDavid Jin Oct 28, 2016 to Feb 25, 202013
- PresidentDavid Jin Oct 28, 2016 to Feb 25, 202013
- Chief financial officerLuisa Ingargiola Feb 21, 2017 to Feb 25, 202014
- Chief operating officerMeng Li Oct 28, 2016 to Feb 25, 202015
Board members and other officers (11)
- Chief Strategy OfficerLuisa Ingargiola Jul 13, 2026 to now16
- Board memberLourdes Felix Mar 7, 2023 to now17
- Board memberTevi Troy Jun 14, 2018 to Mar 8, 202318
- Board memberWilliam B. Stilley Iii. Jul 10, 2018 to Mar 8, 202319
- Board memberSteven Andrew Sanders Jul 31, 2018 to now20
- Board memberSteven Philip Sukel May 8, 2017 to Jan 19, 201821
- Board memberYancen Lu Aug 2, 2017 to Feb 25, 202022
- Board memberW. J. Tauzin Nov 15, 2017 to Mar 9, 202323
- Board memberDavid Jin Oct 28, 2016 to Feb 25, 202013
- Board memberMeng Li Oct 28, 2016 to Feb 25, 202015
- Board memberWenzhao Lu Oct 28, 2016 to now24
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorMichael A. Mathews named Mar 12, 202625
Former names
Timeline
Filings
223 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 114 major events, 18 insider forms, 5 large holders, 2 private raises, 64 other. The latest 20:
- Oct 8, 20268-K CURRENT REPORT EDGAR
- Oct 2, 20268-K CURRENT REPORT EDGAR
- Sep 29, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Sep 18, 2026EFFECT EDGAR
- Sep 18, 2026424B3 PROSPECTUS EDGAR
- Sep 18, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
- Sep 18, 2026PRER14A REVISED PRELIMINARY PROXY STATEMENT EDGAR
- Sep 16, 2026S-1/A AMENDMENT NO. 3 TO FORM S-1 EDGAR
- Sep 15, 2026S-1/A AMENDMENT NO. 2 TO FORM S-1 EDGAR
- Sep 14, 20268-K CURRENT REPORT EDGAR
- Aug 31, 20268-K CURRENT REPORT EDGAR
- Aug 31, 20268-K CURRENT REPORT EDGAR
- Aug 26, 2026PRER14A REVISED PRELIMINARY PROXY STATEMENT EDGAR
- Aug 25, 2026S-1/A AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Aug 24, 20268-K CURRENT REPORT EDGAR
- Aug 21, 2026S-8 REGISTRATION STATEMENT EDGAR
- Aug 18, 20268-K CURRENT REPORT EDGAR
- Aug 14, 202610-Q QUARTERLY REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G, 2 filings May 15, 2026 to Aug 14, 202626
- INTRACOASTAL CAPITAL, LLCSCHEDULE 13G/A, 2 filings Mar 5, 2026 to Aug 13, 202627
- Wenzhao LuSC 13D/A, 1 filing Jan 25, 202428
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARMeng Li, Chief executive officer
- 13SEC EDGARDavid Jin, Chief executive officer
- 14
- 15SEC EDGARMeng Li, Chief operating officer
- 16
- 17SEC EDGARLourdes Felix, Board member
- 18SEC EDGARTevi Troy, Board member
- 19
- 20SEC EDGARSteven Andrew Sanders, Board member
- 21SEC EDGARSteven Philip Sukel, Board member
- 22SEC EDGARYancen Lu, Board member
- 23SEC EDGARW. J. Tauzin, Board member
- 24SEC EDGARWenzhao Lu, Board member
- 25
- 26
- 27
- 28